Insider · CIK 0001656998

Azelby Robert

Reports to the SEC for 12 companies · LONDON

sec.gov

Transactions

Companies

Filings

CIK

0001656998

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-29	AUTLAutolus Therapeutics plc · Restricted Share UnitsA Award	Director	AAward	+31.7K sh	—	—	31,667
2026-06-29	AUTLAutolus Therapeutics plc · Share Option (Right to Buy)A Award	Director	AAward	+47.5K sh	—	—	47,500
2026-06-19	TNGXTango Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+35.9K sh	—	—	35,910
2026-06-19	TNGXTango Therapeutics, Inc.A Award	Director	AAward	+5,740 sh	—	—	5,740
2026-06-03	ADCTADC Therapeutics SAF Tax Payment	Director	FTax Payment	−12.6K sh	$3.08	−$38.8K	112,805
2026-06-01	ADCTADC Therapeutics SAA Award	Director	AAward	+45K sh	—	—	125,405
2026-05-05	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−90K sh	—	—	0
2026-05-05	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,697 sh	—	—	0
2026-02-01	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,697 sh	—	—	1,697
2025-11-05	CAHCARDINAL HEALTH INCA Award	Director	AAward	+1,067 sh	—	—	4,085
2025-06-13	ADCTADC Therapeutics SAF Tax Payment	Director	FTax Payment	−12.6K sh	$3.58	−$45.1K	80,405
2025-06-03	ADCTADC Therapeutics SAA Award	Director	AAward	+40K sh	—	—	93,005
2025-02-20	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+90K sh	—	—	90,000
2024-11-06	CAHCARDINAL HEALTH INCA Award	Director	AAward	+1,730 sh	—	—	3,018
2024-06-17	ADCTADC Therapeutics SAS Sale	Director	SSale	−6,995 sh	$2.89	−$20.2K	53,005
2024-06-13	ADCTADC Therapeutics SAA Award	Director	AAward	+40K sh	—	—	60,000
2024-03-15	CAHCARDINAL HEALTH INCA Award	Director	AAward	+1,288 sh	—	—	1,288
2023-08-11	CHINOOK THERAPEUTICS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−28.2K sh	$18.40	−$519K	0
2023-08-11	CHINOOK THERAPEUTICS, INC.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−7,000 sh	—	—	0
2023-04-10	CHINOOK THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+28.2K sh	—	—	28,200
2023-04-10	CHINOOK THERAPEUTICS, INC.Restricted Stock (RSU)(Common Stock)A Award	Director	AAward	+7,000 sh	—	—	7,000
2022-10-31	CLYMClimb Bio, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+500K sh	—	—	500,000
2022-01-27	CLYMClimb Bio, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+500K sh	—	—	500,000
2021-06-10	Clovis Oncology, Inc.Stock Option (right to buy)A Award	Director	AAward	+42.2K sh	—	—	42,223
2020-10-23	IMMUNOMEDICS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−29K sh	—	—	0
2020-10-23	IMMUNOMEDICS INCRestricted Stock UnitD Disposition to Issuer	Director	DDisposition to Issuer	−3,718 sh	—	—	0
2020-06-18	IMMUNOMEDICS INCStock Option (right to buy)A Award	Director	AAward	+6,540 sh	—	—	6,540
2020-06-18	IMMUNOMEDICS INCA Award	Director	AAward	+3,718 sh	—	—	3,718
2020-06-04	Clovis Oncology, Inc.Stock Option (right to buy)A Award	Director	AAward	+40.1K sh	—	—	40,138
2020-02-26	IMMUNOMEDICS INCStock Option (right to buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2019-10-22	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−505K sh	—	—	0
2019-10-22	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−150K sh	—	—	0
2019-10-22	ALDER BIOPHARMACEUTICALS INCRestricted Stock UnitsD Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−15K sh	—	—	0
2019-10-22	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−1M sh	—	—	0
2019-06-06	Clovis Oncology, Inc.Stock Option (right to buy)A Award	Director	AAward	+28.9K sh	—	—	28,882
2019-04-23	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+150K sh	—	—	150,000
2019-02-06	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+505K sh	—	—	505,000
2019-02-06	ALDER BIOPHARMACEUTICALS INCRestricted Stock UnitsA Award	Director, President and CEO	AAward	+15K sh	—	—	15,000
2018-10-11	Clovis Oncology, Inc.Stock Option (right to buy)A Award	Director	AAward	+25.8K sh	—	—	25,848
2018-06-13	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+1M sh	—	—	1,000,000
2018-03-09	Cascadian Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−13.9K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−12.4K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−7,500 sh	—	—	82,112
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−20.6K sh	—	—	61,532
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−25.6K sh	—	—	35,893
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−35.9K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−93.3K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−30K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP & Chief Commercial Officer	DDisposition to Issuer	−98.5K sh	—	—	0
2018-02-12	Juno Therapeutics, Inc.S Sale	EVP & Chief Commercial Officer	SSale	−4,157 sh	$85.55	−$356K	89,614

Recent filings

Accepted (ET)
Jul 14
Azelby Robert0001730463-26-000093
SEC(opens sec.gov)
Jun 234
Azelby Robert0001193125-26-279871
SEC(opens sec.gov)
Jun 34
Azelby Robert0001628280-26-040493
SEC(opens sec.gov)
May 54
Azelby Robert0001656998-26-000006
SEC(opens sec.gov)
Feb 24
Azelby Robert0001656998-26-000002
SEC(opens sec.gov)
Nov 64
Azelby Robert0001656998-25-000004
SEC(opens sec.gov)
Jun 174
Azelby Robert0001628280-25-031890
SEC(opens sec.gov)
Jun 54
Azelby Robert0001628280-25-029736
SEC(opens sec.gov)
Feb 244
Azelby Robert0001562180-25-001542
SEC(opens sec.gov)
Nov 74
Azelby Robert0000721371-24-000152
SEC(opens sec.gov)
Jun 184
Azelby Robert0001628280-24-028993
SEC(opens sec.gov)
Jun 144
Azelby Robert0001628280-24-028357
SEC(opens sec.gov)
Mar 184
Azelby Robert0000721371-24-000019
SEC(opens sec.gov)
Aug 114
Azelby Robert0001209191-23-045412
SEC(opens sec.gov)
Apr 124
Azelby Robert0001209191-23-024111
SEC(opens sec.gov)

Companies

Address

THE MEDIAWORKS, WHITE CITY C/O AUTOLUS THERAPEUTICS PLC

LONDON, W12 7FP